It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Research analysts at StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology ...
an E-selectin anatomist in phase 1. It's worth noting that this isn't Pfizer's first deal in SCD. In 2011 it paid $340 million for rights to rivipansel, a pan-selectin antagonist developed by ...
Investigating clinical associations between genomic alterations and prostate cancer lineage states using circulating tumor cell RNA sequencing. This is an ASCO Meeting Abstract from the 2025 ASCO ...
The importance of these molecules in the development of atherosclerosis is demonstrated in mice deficient in molecules such as intercellular adhesion molecule 1 (ICAM 1) and P selectin ... such as ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Macrophages are important components of the internal immune cells, which profoundly affects the internal ...
The rumors turned out to be correct, even if most were styling it with a capital E rather than a lower-case one: the iPhone SE 4 is officially named the iPhone 16e. One question is what the e ...
I’m concerned less with the “e” (which, I’m sure, doesn’t stand for any one thing, though Apple would probably be plenty happy if it was interpreted as for “efficiency”) than with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback